Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Zapata quantifies $21m series A
The Engine has participated in a $21m series A round for its portfolio company Zapata Computing, a quantum technology spinout of Harvard University.
Corporates affirm Affectiva interest with $26m
Aptiv and CAC Holdings joined corporate venturing units Trend Forward Capital and Motley Fool Ventures in a $26m round that almost doubled the MIT spinout's funding.
Cytora assesses $32.6m series B
Cambridge Innovation Capital and Parkwalk Advisors have both returned to back a $32.6m series B round for Cytora, an insurance technology spinout of Cambridge.
Boehringer Ingelheim regenerates Agomab
Boehringer Ingelheim Venture Fund has participated in a $23.8m round for the antibody developer spun out of University of Turin.
Cardinal Analytx processes series B
Stanford spinout Cardinal Analytx has raised $20.6m out of a targeted $29.3m, adding to a $6.1m series A round backed by Stanford-StartX Fund in 2017.
Elicio elicits $30m
Building on work at MIT’s Koch Institute of Integrative Cancer Research, Elicio hopes to begin patient studies in 2020 for pancreatic, colorectal, head and neck cancers.
Exscientia and Celgene sign $25m collaboration
University of Dundee intelligent drug design spinout Exscientia has struck a business deal with Celgene after raising series B funding from the corporate in January.
Gintel Technology to purify $30m round
Kao Yuan University's Gintel has created water quality monitoring systems that can provide information on 50 parameters of toxicity and recommend remedies.

Other News

Axial Biotherapeutics takes in $25m series B
Heritage Medical Systems has backed a $25m series B round for the Caltech spinout, which is developing therapies for Parkinson’s and Autism spectrum disorder.
GV sees Lightmatter for series A extension
Alphabet's venturing unit has led a $22m series A extension for MIT spinout Lightmatter, which increased the round's total to $33m.
Anaveon validates Novartis for series A
Zurich immuno-oncology spinout Anaveon raised $35.1m from Novartis Venture Fund and Syncona in addition to seed-stage notes converted by the UZH Life Sciences Fund.
U-M commits $20m to four spinouts
University of Michigan will supply an initial $2.75m in funding to MemryX, Ripple Science, GreenMark Biomedical, and Give and Take, and could invest as much as $20m altogether.
Neuspera restimulates $26m series B
Neuspera Medical has secured a $12m extension to bring its series B round to the targeted $26m close, with all investors from the first tranche returning.
KenSci foretells $22m series B
The UW-founded healthcare forecasting software developer has collected $30.5m in all from backers including OUP and a unit of compliance firm UL.

Editor's Picks

Tel Aviv partners with Tata
Tel Aviv University announces $20m commercialisation fund with Tata Industries.
UK graphene research nets $35m backing
Cell Medica raises $26.5m
Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.
Revolymer sticks to AIM in IPO
Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.
test reg